Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Pallebage Gamarallage, Menuka ^a,b   Lam, Virginie ^a,b   Takechi, Ryusuke ^a,b   Galloway, Susan ^a,b   Clark, Karin ^a,b   Mamo, John ^a,b  

^a CURTIN UNIVERSITY   (Australia)

^b Australian Technology Network   (Australia)

Author keywords

Alzheimers disease; Atorvastatin; Blood brain barrier; Ibuprofen; Pravastatin; Saturated fatty acids

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; I 110; IBUPROFEN; IMMUNOGLOBULIN G; PRAVASTATIN; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DYSFUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; IMMUNOFLUORESCENCE MICROSCOPY; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MOUSE; NONHUMAN;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS B; BLOOD-BRAIN BARRIER; BRAIN; DIET, HIGH-FAT; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; IBUPROFEN; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; PRAVASTATIN; PYRROLES;

MUS;

EID: 84866150126     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-117     Document Type: Article

References (58)

1. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A, BMJ 2001 322 1447 1451 10.1136/bmj.322.7300.1447 11408299 (Pubitemid 32575406)
2. Vascular factors and Alzheimer disease. Skoog I, Kalaria RN, Breteler MMB, Alz Dis Assoc Dis 1999 13 106 S114
3. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM, Ann Rev 1997 42 776 782 (Pubitemid 27481550)
4. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Laitinen M, Ngandu T, Rovio S, Helkala E, Uusitalo U, Viitanen M, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M, Dement Geriatr Cogn Disord 2006 22 99 107 10.1159/000093478 16710090
5. Lipids, diet and Alzheimer's disease: and extended summary. Petot GJ, Friedland RP, J Neurol Sci 2004 226 31 33 10.1016/j.jns.2004.09.007 15537515 (Pubitemid 39505401)
6. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. Beckmann N, Schuler A, Mueggler T, Meyer EP, Wiederhold K-H, Staufenbiel M, Krucker T, J Neurosci 2003 23 8453 8459 13679413 (Pubitemid 37158744)
7. Age-dependent increase in ischemic brain injury in wild-type mice and in mice lacking the inducible nitric oxide synthase gene. Nagayama M, Aber T, Nagayama T, Ross ME, Iadecola C, J Cereb Blood Flow Metab 1999 19 661 666 10366196 (Pubitemid 30161218)
8. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C, Brain 2007 130 2310 2319 10.1093/brain/awm156 17638859 (Pubitemid 47327629)
9. The blood-brain barrier in health and chronic neurodegenerative disorders. Zlokovic BV, Neuron 2008 57 178 201 10.1016/j.neuron.2008.01.003 18215617
10. Perivascular astrocytes within Alzheimer's disease plaques. Cullen KM, Neuroreport 1997 8 1961 1966 10.1097/00001756-199705260-00033 9223085 (Pubitemid 27314317)
11. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A, Neurology 1996 46 1592 1596 10.1212/WNL.46.6.1592 8649554 (Pubitemid 26185777)
12. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Kalaria RN, Cerebrovas Brain Met Rev 1992 4 226 60
13. Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Wisniewski HM, Vorbrodt AW, Wegiel J, Ann Ny Acad Sci 1997 826 161 172 10.1111/j.1749-6632.1997.tb48468.x 9329688 (Pubitemid 27478038)
14. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR, Mt Sinai J Med: J Translational and Personalized Med 2010 77 82 102
15. Vascular pathology in Alzheimer's disease. Miyakawa T, Psychogeriatrics 2010 10 39 44 10.1111/j.1479-8301.2009.00294.x 20608291
16. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellican M, Rizzo C, Scapagnini G, Vasto S, Rejuvenation Res 2010 13 301 313 10.1089/rej.2009.0993 20462385
17. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM, Am J Clin Nutr 2009 90 170 176 10.3945/ajcn.2008.27037 19474131
18. Thoughts on B-vitamins and dementia. Morris M, Schneider J, Tangney C, J Alzheimers Dis 2006 9 429 433 16917152 (Pubitemid 44253358)
19. Benefits from dietary polyphenols for brain aging and Alzheimers disease. Rossi L, Mazzitelli S, Arciello M, Capo C, Rotilio G, Neurochem Res 2008 33 2390 2400 10.1007/s11064-008-9696-7 18415677
20. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Jaturapatporn D, Isaac Mokhtar Gad El Kareem N, McCleery J, Tabet N, Cochrane Db Syst Rev 2012 2 D006378
21. Protective effects of NSAIDs on the development of Alzheimer disease. Vlad SC, Miller DR, Kowall NW, Felson DT, Neurology 2008 70 1672 1677 10.1212/01.wnl.0000311269.57716.63 18458226 (Pubitemid 351644133)
22. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Imbimbo B, Solfrizzi V, Panza F, Front Aging Neurosci 2010 2 1 14 20552041
23. Extended results of the Alzheimers disease anti-inflammatory prevention trial. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN, Alzheimers Dement 2011 7 402 411 10.1016/j.jalz.2010.12.014 21784351
24. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Choi J, Jenkins B, Carreras I, Kaymakcalan S, Cormier K, Kowall N, Dedeoglu A, Exp Neurol 2010 223 377 384 10.1016/j.expneurol.2009.07.032 19679126
25. Ibuprofen suppresses interleukin-1 induction of pro-amyloidogenic 1-antichymotrypsin to ameliorate -amyloid (A) pathology in Alzheimer's models. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM, Neuropsychopharmacology 2005 30 1111 1120 10.1038/sj.npp.1300668 15688088 (Pubitemid 40720969)
26. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Dufouil C, Richard F, Fievet N, Dartigues J, Ritchie K, Tzourio C, Amouyel P, Alperovitch A, Neurology 2005 64 1531 1538 10.1212/01.WNL.0000160114.42643.31 15883313 (Pubitemid 40617688)
27. Lipid lowering agents, Cognitive decline, and dementia: the three-city study. Ancelin M-L, Carrière I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy A-M, Ritchie K, J Alzheimers Dis 2012 30 629 637 22451317
28. Statins for the treatment of dementia. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P, Cochrane Db Syst Rev 2010 Published online:CD007514
29. Age-varying association between statin use and incident Alzheimer's disease. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JCS, Larson EB, J Am Geriatr Soc 2010 58 1311 1317 10.1111/j.1532-5415.2010.02906.x 20533968
30. Statins and the risk of dementia. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA, Lancet 2000 356 1627 1631 10.1016/S0140-6736(00)03155-X 11089820
31. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G, Arch Neurol 2000 57 1439 1443 10.1001/archneur.57.10.1439 11030795
32. Effects of atorvastatin on blood-brain barrier permeability during l-NAME hypertension followed by angiotensin-II in rats. Kalayci R, Kaya M, Elmas I, Arican N, Ahishali B, Uzun H, Bilgic B, Kucuk M, Kudat H, Brain Res 2005 1042 184 193 10.1016/j.brainres.2005.02.044 15854590 (Pubitemid 40591728)
33. Pitavastatin strengthens the barrier integrity in primary cultures of rat brain endothelial cells. Morofuji Y, Nakagawa S, So G, Hiu T, Horai S, Hayashi K, Tanaka K, Suyama K, Deli M, Nagata I, Niwa M, Cellr Mol Neurobiol 2010 30 727 735 10.1007/s10571-010-9497-9
34. Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk. Pallebage-Gamarallage MMS, Takechi R, Lam V, Galloway S, Dhaliwal S, Mamo JCL, Atherosclerosis Supp 2010 11 49 54
35. Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid- Takechi R, Galloway S, Pallebage-Gamarallage MMS, Wellington CL, Johnsen RD, Dhaliwal SS, Mamo JCL, Br J Nutr 2010 103 652 662 10.1017/S0007114509992194 19860996
36. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS, Diabetes 2005 54 2977 2982 10.2337/diabetes.54.10.2977 16186401 (Pubitemid 41401095)
37. Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor-an animal study. Dabhi J, Solanki J, Mehta A, Indian J Exp Biol 2008 46 476 481 18697608
38. Ibuprofen protects low density lipoproteins against oxidative modification. Zapolska-Downar D, Zapolski-Downar A, Bukowska H, Galka H, Naruszewicz M, Life Sci 1999 65 2289 2303 10.1016/S0024-3205(99)00496-8 10597884 (Pubitemid 29531032)
39. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Shitara Y, Sugiyama Y, Pharmacol Ther 2006 112 71 105 10.1016/j.pharmthera.2006. 03.003 16714062 (Pubitemid 44301483)
40. Synaptic localization of a functional NADPH oxidase in the mouse hippocampus. Tejada-Simon MV, Serrano F, Villasana LE, Kanterewicz BI, Wu G-Y, Quinn MT, Klann E, Mol Cell Neurosci 2005 29 97 106 10.1016/j.mcn.2005.01.007 15866050 (Pubitemid 40603884)
41. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY, Sun GY, Brain Res 2006 1090 182 189 10.1016/j.brainres.2006.03.060 16650838 (Pubitemid 43817927)
42. Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Kril J, Patel S, Harding A, Halliday G, J Neurol Neurosurg Psychiatry 2002 72 747 751 10.1136/jnnp.72.6.747 12023418 (Pubitemid 34557018)
43. Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. Mann D, Yates P, Marcyniuk B, J Neurol Sci 1985 69 139 159 10.1016/0022-510X(85)90129-7 3162000 (Pubitemid 15074612)
44. Use of structural imaging to study the progression of Alzheimer's disease. Smith AD, Jobst KA, Brit Med Bull 1996 52 575 586 10.1093/ oxfordjournals.bmb.a011568 8949258 (Pubitemid 26329155)
45. Beneficial cardiovascular pleiotropic effects of statins. Davignon J, Circulation 2004 109 II-39 III-43 10.1161/01.CIR.0000131517.20177.5a
46. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L, Vasc Health Risk Manag 2007 3 567 577 18078008 (Pubitemid 350104113)
47. Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase III. McGown CC, Brown NJ, Hellewell PG, Reilly CS, Brookes ZLS, Brit J Anaesth 2010 104 183 190 10.1093/bja/aep361 20086063
48. Mechanisms of action of dietary fatty acids in regulating the activation of vascular endothelial cells during atherogenesis. Christon RA, Nutr Rev 2003 61 272 279 10.1301/nr.2003.aug.272-279 13677589 (Pubitemid 37259927)
49. Diet and endothelial function. Cuevas A, Germain A, Biol Res 2004 37 225 230 15455651 (Pubitemid 39328261)
50. Dietary saturated and unsaturated fats as determinants of blood pressure and vascular function. Hall W, Nutr Res Rev 2009 22 18 38 10.1017/ S095442240925846X 19243668
51. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, Rye K-A, Barter PJ, Celermajer DS, J Am Coll Cardiol 2006 48 715 720 10.1016/j.jacc.2006.04.080 16904539 (Pubitemid 44175720)
52. Hamsters fed diets high in saturated fat have increased cholesterol accumulation and cytokine production in the aortic arch compared with cholesterol-fed hamsters with moderately elevated plasma non-HDL cholesterol concentrations. Alexaki A, Wilson TA, Atallah MT, Handelman G, Nicolosi RJ, J Nutr 2004 134 410 415 14747681 (Pubitemid 38141825)
53. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. Hennig B, Toborek M, McClain C, J Am Coll Nutr 2001 20 97 105 11349944 (Pubitemid 32423599)
54. Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease. Lam V, Takechi R, Pallebage-Gamarallage MMS, Galloway S, Mamo JCL, Neurosci Lett 2011 492 160 164 10.1016/j.neulet.2011.02.001 21310214
55. Blood-brain barrier alterations in ageing and dementia. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, Bogdanovic N, J Neurol Sci 2009 283 99 106 10.1016/j.jns.2009.02.321 19264328
56. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F, Pharmacol Ther 1999 84 413 428 10.1016/S0163-7258(99)00045-5 10665838
57. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Schachter M, Fundam Clin Pharmacol 2005 19 117 125 10.1111/j.1472-8206. 2004.00299.x 15660968 (Pubitemid 40204354)
58. A diet enriched in docosahexanoic acid exacerbates brain parenchymal extravasation of apo B lipoproteins induced by chronic ingestion of saturated fats. Pallebage-Gamarallage M, Lam V, Takechi R, Galloway S, Mamo JCL, Int J Vasc Med 2012 2012 647 689